All In Biotech

Drug Trial Radar · NCT01242488

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Randomized, Double-blind, Placebo-controlled, Dose Ranging Study With an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects With Rheumatoid Arthritis Having Previously Failed TNF-blocker Therapy

Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 221 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

221

Actual

Start

Nov 2010

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Nov 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • CDP6038Biological

    60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10

  • CDP6038Biological

    120 mg sc at Weeks 0, 2, 4 6, 8, and 10

  • CDP6038Biological

    240 mg sc at Weeks 0, 2, 4 6, 8, and 10

  • Tocilizumab (Actemra or RoActemra)Biological

    8 mg/kg intravenously (iv) at Weeks 0, 4 and 8

  • CDP6038Biological

    60 mg sc at Weeks 0, 4 and 8

  • CDP6038Biological

    240 mg sc at Weeks 0, 4 and 8

  • CDP6038Biological

    120 mg sc at Weeks 0, 4 and 8

  • Placebo scOther

    0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10

  • Placebo scOther

    0.9% Sodium chloride for injection at Weeks 2, 6 and 10

  • Placebo ivOther

    0.9% Sodium chloride for injection at Weeks 0, 4 and 8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Disease Activity Score (C-reactive protein) [DAS28(CRP)] for CDP6038 and placeboTime frame: Baseline, Week 12

Locations

82 sites in 3 countries. Site status is shown where the registry gives one.

  • 166

    Mesa, Arizona

  • 154

    Paradise Valley, Arizona

  • 118

    Scottsdale, Arizona

  • 103

    Hot Springs, Arkansas

  • 125

    Jonesboro, Arkansas

  • 127

    Covina, California

  • 148

    La Jolla, California

  • 184

    Long Beach, California

  • 177

    Los Angeles, California

  • 104

    Palo Alto, California

  • 149

    Sacramento, California

  • 158

    San Diego, California

  • 129

    Santa Maria, California

  • 164

    Upland, California

  • 107

    Wildomar, California

  • 141

    Hamden, Connecticut

  • 137

    Norwalk, Connecticut

  • 101

    Trumbull, Connecticut

  • 111

    Lewes, Delaware

  • 176

    Aventura, Florida

  • 186

    Daytona Beach, Florida

  • 151

    DeBary, Florida

  • 114

    Jupiter, Florida

  • 183

    Pinellas Park, Florida

  • 178

    Sarasota, Florida

  • 140

    South Miami, Florida

  • 157

    Tampa, Florida

  • 130

    Gainesville, Georgia

  • 162

    Newnan, Georgia

  • 153

    Savannah, Georgia

  • 113

    Stockbridge, Georgia

  • 116

    Idaho Falls, Idaho

  • 160

    Moline, Illinois

  • 156

    Rock Island, Illinois

  • 168

    Springfield, Illinois

  • 133

    Cedar Rapids, Iowa

  • 172

    Kansas City, Kansas

  • 185

    Saint Clair Shores, Michigan

  • 112

    St Louis, Missouri

  • 134

    St Louis, Missouri

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.